Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M0324 Monotherapy and Combinations in Advanced Solid Tumors
NCT07166601Phase 1Recruiting
- Sponsor
- EMD Serono
- Start
- Oct 2025
- Primary completion
- Feb 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of M0324 in solid tumor and pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities and Treatment-Emergent Adverse Events. Started Oct 2025; status: recruiting.
02
Drugs
M0324
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07166601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166601.